Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Somaiah N, et al. Among authors: barreto c. Lancet Oncol. 2022 Sep;23(9):1156-1166. doi: 10.1016/S1470-2045(22)00392-8. Epub 2022 Aug 4. Lancet Oncol. 2022. PMID: 35934010 Clinical Trial.
Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues.
Parra ER, Zhai J, Tamegnon A, Zhou N, Pandurengan RK, Barreto C, Jiang M, Rice DC, Creasy C, Vaporciyan AA, Hofstetter WL, Tsao AS, Wistuba II, Sepesi B, Haymaker C. Parra ER, et al. Among authors: barreto c. Sci Rep. 2021 Feb 25;11(1):4530. doi: 10.1038/s41598-021-83858-x. Sci Rep. 2021. PMID: 33633208 Free PMC article.
The immune landscape of undifferentiated pleomorphic sarcoma.
Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. Lazcano R, et al. Front Oncol. 2022 Oct 12;12:1008484. doi: 10.3389/fonc.2022.1008484. eCollection 2022. Front Oncol. 2022. PMID: 36313661 Free PMC article.
Lag3: From Bench to Bedside.
Aroldi F, Saleh R, Jafferji I, Barreto C, Saberian C, Middleton MR. Aroldi F, et al. Among authors: barreto c. Cancer Treat Res. 2022;183:185-199. doi: 10.1007/978-3-030-96376-7_6. Cancer Treat Res. 2022. PMID: 35551660 Review.
Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study.
Aguiar Júnior P, Barreto CMN, Roitberg F, Lopes Júnior G, Giglio AD. Aguiar Júnior P, et al. Sao Paulo Med J. 2019 Nov-Dec;137(6):505-511. doi: 10.1590/1516-3180.2018.0256170919. Sao Paulo Med J. 2019. PMID: 32159636 Free PMC article.
252 results